Literature searchThis meta-analysis

Literature search

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement20. Our meta-analysis searches were conducted using the PubMed, Web of Science Knowledge and Cochrane Library databases from their inception dates to August 1, 2014. The search applied the following search terms: “rituximab”, “CD20”, and “nephrotic syndrome”.
Study selection criteria and study types

RCTs or comparative cohort studies that evaluated the efficacy and safety of rituximab in treating pediatric patients with refractory NS were included.
Type of participants

The patients were diagnosed with NS at 18 years of age and younger.
Type of interventions

Rituximab and current immunotherapy were compared. Different schedules and modalities of rituximab were included.
Analyzed outcomes

The primary outcome was relapse-free survival. The secondary outcomes were (1) complete remission events, (2) biological indicators, including proteinuria, serum albumin, serum cholesterol and serum creatinine, and (3) adverse events.
Study selection and data extraction

The references obtained from the electronic search were evaluated by two independent reviewers (Zhao Z and Liao G) using a study selection form. The initial assessment was based on screening the titles and abstracts; studies that did not meet the inclusion criteria were excluded. The studies that were not excluded after an initial evaluation were retrieved for full text screening and, according to the inclusion criteria, it was determined whether the study should be included in our analysis. In cases of disagreement, the final decision for inclusion was made by consensus among the authors. Review articles, case reports, comments, meeting abstracts and editorials were excluded.

The data were extracted by two independent reviewers (Zhao Z and Liao G). The extraction data included the (1) study characteristics (authors, publication year), (2) study design features, (3) study participants (e.g., eligibility criteria and baseline characteristics), (4) study interventions, and (5) study outcomes (efficacy and safety outcomes).

Hasil (Bahasa Indonesia) 1:

Sastra pencarianMeta-analisis ini dilakukan menurut pilihan pelaporan item untuk review sistematis dan Meta-analisis statement20. Kami pencarian meta-analisis yang dilakukan menggunakan database PubMed, Web ilmu pengetahuan dan Cochrane Library dari tanggal awal mereka untuk 1 Agustus 2014. Pencarian diterapkan istilah pencarian berikut: "rituximab", "CD20", dan "nefrotik syndrome".Kriteria seleksi studi dan jenis studiDimasukkan RCTs atau Studi kohort perbandingan yang dievaluasi efektivitas dan keamanan rituximab dalam mengobati pediatric pasien dengan bahan tahan api NS.Jenis pesertaPasien yang didiagnosis dengan NS di 18 tahun dan lebih muda.Jenis intervensiRituximab dan imunoterapi saat ini dibandingkan. Jadwal berbeda dan modalitas rituximab dimasukkan.Hasil yang dianalisisHasil utama pada kelangsungan hidup kambuh. Hasil sekunder adalah peristiwa (1) pengampunanNya, indikator (2) biologis, termasuk proteinuria, serum albumin, kolesterol serum dan kreatinin serum, dan (3) efek samping.Seleksi studi dan data ekstraksiRujukan-rujukan yang Diperoleh dari pencarian elektronik dievaluasi oleh dua pengulas independen (Zhao Z dan Liao G) menggunakan bentuk seleksi studi. Penilaian awal didasarkan pada pemutaran judul dan abstrak; studi yang tidak memenuhi kriteria inklusi dikeluarkan. Studi-studi yang tidak dikecualikan setelah evaluasi awal yang diambil untuk teks lengkap skrining dan, menurut kriteria inklusi, itu ditentukan Apakah studi harus dimasukkan dalam analisis kami. Dalam kasus perselisihan, keputusan akhir untuk dimasukkan dibuat oleh konsensus di antara para penulis. Review artikel, laporan, komentar, Rapat abstrak dan editorial dikeluarkan.Data diambil oleh dua pengulas independen (Zhao Z dan Liao G). Data ekstraksi termasuk karakteristik (1) studi (penulis, tahun publikasi), (2) belajar fitur desain, (3) peserta penelitian (misalnya, kriteria dan dasar karakteristik), (4) Kajian intervensi dan (5) Kajian hasil (hasil efficacy & safety).